Free Trial

Agenus (AGEN) Stock Price, News & Analysis

+0.79 (+7.10%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.02 million shs
Average Volume
682,893 shs
Market Capitalization
$250.10 million
P/E Ratio
Dividend Yield
Price Target

Agenus MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
487.7% Upside
$70.00 Price Target
Short Interest
16.80% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.36mentions of Agenus in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($9.70) to ($8.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.68 out of 5 stars

Medical Sector

235th out of 921 stocks

Biological Products, Except Diagnostic Industry

24th out of 135 stocks

AGEN stock logo

About Agenus Stock (NASDAQ:AGEN)

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Stock Price History

AGEN Stock News Headlines

Agenus sets FDA meeting for cancer therapy path
Agenus Inc. (NASDAQ:AGEN) Short Interest Up 25.1% in April
Agenus: Q1 Earnings Snapshot
Agenus Reports First Quarter 2024 Results
Time Is Running Out For Agenus To Raise Cash
Agenus Inc. (AGEN)
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$161.42 million
Book Value
($9.06) per share


Free Float
Market Cap
$250.10 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Founder, Executive Chairman & CEO
    Comp: $1.34M
  • Ms. Christine M. Klaskin (Age 58)
    VP of Finance, Principal Financial Officer & Principal Accounting Officer
    Comp: $407.44k
  • Dr. Steven J. O'Day M.D. (Age 63)
    Ph.D., Chief Medical Officer
    Comp: $970.98k
  • Craig Winter
    Chief Information Officer
  • Mr. Zack Armen
    Head of Investor Relations
  • Ms. Tracy Mazza Clemente
    Chief People Officer
  • Mr. Alfred Dadson
    Chief Manufacturing Officer
  • Mr. Eric Humes
    Chief Quality Officer
  • Dr. Todd Jude Yancey M.D.
    Member of Advisory Board & Chief Strategic Advisor
  • Dr. Robin G. Taylor M.B.A.
    Ph.D., Chief Commercial Officer

AGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price target for 2024?

3 equities research analysts have issued 1 year target prices for Agenus' shares. Their AGEN share price targets range from $40.00 to $100.00. On average, they expect the company's stock price to reach $70.00 in the next year. This suggests a possible upside of 487.7% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2024?

Agenus' stock was trading at $16.5580 at the start of the year. Since then, AGEN shares have decreased by 28.1% and is now trading at $11.91.
View the best growth stocks for 2024 here

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our AGEN earnings forecast

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) issued its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $2.20. The biotechnology company had revenue of $83.80 million for the quarter, compared to analysts' expectations of $54.21 million.

What ETFs hold Agenus' stock?

ETFs with the largest weight of Agenus (NASDAQ:AGEN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

When did Agenus' stock split?

Shares of Agenus reverse split on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
Who are Agenus' major shareholders?

Agenus' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (169.59%), GSA Capital Partners LLP (6.27%), Oracle Investment Management Inc. (5.08%), Key Client Fiduciary Advisors LLC (4.10%), Acadian Asset Management LLC (3.73%) and Hennion & Walsh Asset Management Inc. (2.67%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Garo H Armen and Steven J O'day.
View institutional ownership trends

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGEN) was last updated on 5/23/2024 by Staff

From Our Partners